Conference Presentations, Posters & Abstracts
—
Past Pharsight®
Contributions
2009
November
Prins NH, Green M, Haughie S, Johnson P, Martin SW. Use of model based meta-analysis combining patient-level with summary-level data using multilevel random effects to provide a quantitative assessment of the clinical efficacy (IPSS) profile and competitive positioning of a PDE5 inhibitor (UK369,003) for the treatment of benign prostatic hyperplasia (BPH). [poster presentation]. Presented at: AAPS Annual Meeting; November 8-12, 2009; Los Angeles, California.
October
Dykstra K, Hodge L, Poland B, Carrothers TJ. Methods for Developing Differentiated Drug Products. [invited presentation]. Presented at: DIA/FDA/PhRMA Meeting on Modeling and Simulation in Drug Development: Quantitative Approaches for Decision Making. October 28-29, 2009; Bethesda, Maryland.
The following was presented at the 2nd American Conference on Pharmacometrics (ACoP); October 4-7, 2009; Mashantucket, Connecticut:
Bruno R. A Modeling Framework to Simulate Motesanib Efficacy in Thyroid Cancer. [podium presentation].
Dykstra K. Simulation Graphics to Enable Model-Based Decision Making. [podium presentation].
Poland B. Optimal Sequencing of Interdependent Drug Development Programs. [poster presentation].
Carrothers TJ, Walker J, Khariton T, Habtemariam B, Mager D, Rohatagi S.
Population Models Correlating Exposure to Efficacy and Safety Markers following Oral Administration of a Novel Fructose-1,6-Bisphosphatase Inhibitor in Type 2 Diabetic Subjects. [poster presentation].
Green M, Carrothers TJ. Quantitative Understanding of the Impact of Evolving Rescue Criteria in the Assessment of Anti-diabetic Compounds. [poster presentation].
Ezzet F, Young L, Darwish M. A Mixed-Effects Hazard Model to Compare the PK/PD of Armodafinil and Modafinil in Patients with Excessive Sleepiness Associated with Shift Work Disorder. [poster presentation].
Lindbom L, Claret L, Andre V, Cleverly A, de Alwis D, Bruno R. A Drug Independent Tumor Size Reduction-Survival Model in Advanced Ovarian Cancer to Support Early Clinical Development Decisions. [poster presentation].
Kastrissios H, Walker J, Khariton T, Kshirsagar S, Habtemariam B, Mager D, Rohatagi S. . A Population Pharmacokinetic Model for a Novel Oral Hypoglycemic Formed In Vivo: Comparing the Use of Active Metabolite Data Alone versus Using Data of Upstream and Downstream Metabolites. [poster presentation].
Chanu P, Reigner B, Schultze N, Gieschke R, Charoin JE, Frey N. Decisive support of Modeling & Simulation for getting drug approval in the context of safety concern on the drug class. [poster presentation].
Moore H. Mathematical optimization of therapies for chronic hepatitis C virus (HCV) infection. [poster presentation].
Lu JF, Claret L, Sutjandra L, Kuchimanchi M, Stepan DE, Bruno R, Melara R, Sun YN. Population Pharmacokinetic (PK)/Pharmacodynamic (PD) Modeling and Simulations for Exposure–Tumor Response Relationships: Motesanib in a Phase 2 Thyroid Cancer Study. [poster presentation]
September
Carrothers TJ, Fredrickson JO. The Benefits of Model-Based Approaches to the Development of Anti-Diabetic Compounds. [poster & podium presentation]. Presented at: American College of Clinical Pharmacology 38th Annual Meeting; September 13-15, 2009; San Antonio, Texas.
Marier JF, Pheng L, Trinh MM, Brunet JS, Anderson K, Gisburne S, Porubek D. Pharmacokinetics of SN2310, an Injectable Emulsion that Incorporates a New Derivative of SN-38, the Active Metabolite of Irinotecan, in Patients with Advanced Solid Tumors. [poster presentation]. Presented at: American College of Clinical Pharmacology 38th Annual Meeting; September 13-15, 2009; San Antonio, Texas.
Poland B. Optimal Sequencing of Interdependent Drug Development Programs. [poster & podium presentation]. Presented at: American College of Clinical Pharmacology 38th Annual Meeting; September 13-15, 2009; San Antonio, Texas.
July
Quinn K, Brigham B, Kuwabara-Wagg J, Cabrera C, Dreyer M, Goldbach E, Hu K, Lee M, Liao A, Green M, Ness D, Santiago P, Samant B, Soriano F, Webb S, Basi GS, Sauer JM. Pharmacokinetic and Pharmacodynamic Analysis of A Novel Gamma Secretase Inhibitor in a Non-transgenic Aβ Mouse Efficacy Model. [poster presentation]. Presented at: Alzheimer's Association International Conference on Alzheimer's Disease (ICAD); July 11-16, 2009; Vienna, Austria.
Guigliano R, Rohatagi S, Kastrissios H, Green M, Carrothers TJ, Mendell J, Antman E, Salazar D. The Relationship Between Oral Factor Xa (FXa) Inhibitor DU-176b Pharmacokinetics (PK) and The Probability of Bleeding Events (BE) in Patients with Atrial Fibrillation (AF). [poster presentation]. Presented at: International Society on Thrombosis and Haemostasis (ISTH) 22nd Congress: July 11-16, 2009; Boston, Massachusetts.
June
DePaoli AM, Dunn F, Fredrickson J, Higgins L. INT131: A Selective PPARg Modulator (SPPARM) Significantly Lowers Glucose Without Typical Thiazolidinedione (TZD) Side Effects in Patients with Type 2 Diabetes. [oral presentation]. Presented at: American Diabetes Association 69th Scientific Sessions; June 5-9, 2009; New Orleans, Louisiana.
Prins NH, Green M, Haughie S, Johnson P, Martin SW. Use of model based meta-analysis combining patient-level with summary-level data using multilevel random effects to provide a quantitative assessment of the clinical efficacy (IPSS) profile and competitive positioning of a PDE5 inhibitor (UK369,003) for the treatment of benign prostatic hyperplasia (BPH). [poster presentation]. Presented at: 18th Annual Meeting of the Population Approach Group in Europe (PAGE); June 23-26, 2009; St. Petersburg, Russia.
Johnson P, Martin SW, Milligan P, Cleeton A, Healtherington A, Crossland A, Haughie S, Lamb J, Tamimi N, Prins NH. Enhanced quantitative drug development (EQDD) of a selective PDE5 inhibitor for the treatment of benign Prostatic hyperplasia (BPH). [poster presentation]. Presented at: 18th Annual Meeting of the Population Approach Group in Europe (PAGE); June 23-26, 2009; St. Petersburg, Russia.
Prins NH, Jonsson F, Haughie S, Johnson P, Martin SW. Comparison of a maximum likelihood versus a full bayesian method to jointly model individual with summary level data. [poster presentation]. Presented at: 18th Annual Meeting of the Population Approach Group in Europe (PAGE); June 23-26, 2009; St. Petersburg, Russia.
Prins NH, Cleton A, Magnusson MO, Johnson P, Heatherington A. Characterization of the population pharmacokinetics of UK-369,003 using a semi-mechanistic model. [poster presentation]. Presented at: 18th Annual Meeting of the Population Approach Group in Europe (PAGE); June 23-26, 2009; St. Petersburg, Russia.
Jonsson F, Fleury A, Lavé T. A pharmacokinetic-pharmacodynamic model for ECG pattern changes in dog and monkey. [poster presentation]. Presented at: 18th Annual Meeting of the Population Approach Group in Europe (PAGE); June 23-26, 2009; St. Petersburg, Russia.
Wagg JK, Green M. Estimation of cortical amyloid beta turnover rates. [poster presentation]. Presented at: 18th Annual Meeting of the Population Approach Group in Europe (PAGE); June 23-26, 2009; St. Petersburg, Russia.
Poland B. PK/PD Modeling Shows Adherence Can Become Critical With New HCV Regimens. [invited presentation]. Presented at: 4th International Workshop on Clinical Pharmacology of Hepatitis Therapy; June 26-27, 2009; Boston, Massachusetts.
May
Bruno R, Lu JF, Sun YN, Claret L. Simulation of survival with first- and second-line non-small-cell lung cancer (NSCLC) therapy using a public-domain drug-disease modeling framework. [poster presentation]. Presented at: ASCO Annual Meeting; May 29 - June 2, 2009; Orlando, Florida.
March
Beliveau M, Lemire I, Reimer M, Marier JF, Leonard P, Morseth S.
Pharmacokinetic (PK) Analysis and Optimal Sampling Strategy (OSS) of a Recombinant Protein (ENB-0040) in Adult and Juvenile Rats. [poster presentation].
Presented at: Society of Toxicology Annual Meeting; March 15-19, 2009; Baltimore, Maryland. Posted with permission of sponsor.
Mendell J, Rohatagi S, Rombout F, Kastrissios H, Green M, Carrothers T, Luo R, Salazar D. The Oral Factor Xa Inhibitor DU-176b: Population Pharmacokinetic and Pharmacodynamics Models of Coagulation Biomarkers, Efficacy, and Safety. [oral presentation]. Presented at: ASCPT Annual Meeting; March 18-21, 2009; National Harbor, Maryland.
Zuppa AF, Hammer G, Malviya S, Mouksassi MS, Barrett JS, Kenney B, Royal MA. Pharmacokinetics of IV Acetaminophen in Pediatric Populations. [oral presentation LBIII-A-2]. Presented at: ASCPT Annual Meeting; March 18-21, 2009; National Harbor, Maryland.